Maaike de Boer

4.3k citations

74 papers · 2.1k indexed · h-index 22

Cancer Research top 1%
Oncology top 2%
Pathology and Forensic Medicine top 2%
Pulmonary and Respiratory Medicine top 5%
Surgery top 10%

Co-authors: Vivianne C. G. Tjan‐Heijnen Peter Bult J.A.A.M. van Dijck P. J. van Diest George F. Borm Carolien H. M. van Deurzen Marian B. E. Menke‐Pluymers Agnès J. van de Wouw
Topics: Breast Cancer Treatment Studies (46 papers)Cancer Treatment and Pharmacology (16 papers)Breast Lesions and Carcinomas (16 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: New England Journal of Medicine Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: Netherlands United States Germany

In The Last Decade

Maaike de Boer

71 papers receiving 2.1k citations

Peers

Countries citing papers authored by Maaike de Boer

Since Specialization

Citations

This map shows the geographic impact of Maaike de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maaike de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maaike de Boer more than expected).

Fields of papers citing papers by Maaike de Boer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maaike de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maaike de Boer. The network helps show where Maaike de Boer may publish in the future.

Co-authorship network of co-authors of Maaike de Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Maaike de Boer. A scholar is included among the top collaborators of Maaike de Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maaike de Boer. Maaike de Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[18F]FDG whole-body PET-MR including an integrated breast MR protocol for locoregional and distant staging in breast cancer patients—a feasibility study 2024 ·Insights into Imaging ·Thiemo J. A. van Nijnatten,(unknown),Cristina Mitea,Janneke B. Houwers,Maaike de Boer,Marjolein L. Smidt,Felix M. Mottaghy,Joachim E. Wildberger	0
2	202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study 2024 ·ESMO Open ·(unknown),Sandra M. E. Geurts,J. Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. W. Dercksen,F. Van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),V.C.G. Tjan-Heijnen,Maaike de Boer	1
3	Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed 2023 ·Breast Cancer Research and Treatment ·Lori M. van Roozendaal,(unknown),(unknown),Luc J. A. Strobbe,Maaike de Boer,Gabe S. Sonke,Marissa C. van Maaren,Marjolein L. Smidt	1
4	Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy 2022 ·npj Breast Cancer ·Romy Aarnoutse,Janine Ziemons,(unknown),Judith de Vos‐Geelen,Maaike de Boer,(unknown),Birgit E. P. J. Vriens,(unknown),Agnès J. van de Wouw,Ngoc Giang Le,Koen Venema,Sander S. Rensen,John Penders,Marjolein L. Smidt	28
5	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study 2022 ·Breast Cancer Research and Treatment ·(unknown),(unknown),B.A.M. Heemskerk-Gerritsen,Inge-Marie Obdeijn,Linetta B. Koppert,Claudette E. Loo,Rob A.�E.�M. Tollenaar,Margreet G.E.M. Ausems,Irma van de Beek,(unknown),Maaike de Boer,(unknown),C. Marleen Kets,Matti A. Rookus,(unknown),Marjanka K. Schmidt,Agnes Jager,Maartje J. Hooning	0
6	MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study 2021 ·Cancers ·Renée W. Y. Granzier,Abdalla Ibrahim,Sergey Primakov,Sanaz Samiei,Thiemo J. A. van Nijnatten,Maaike de Boer,Esther M. Heuts,F J Hulsmans,Avishek Chatterjee,Philippe Lambin,Marc B. I. Lobbes,Henry C. Woodruff,Marjolein L. Smidt	26
7	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry 2021 ·International Journal of Cancer ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	10
8	Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls 2021 ·Cancers ·Romy Aarnoutse,(unknown),Janine Ziemons,Judith de Vos‐Geelen,Maaike de Boer,(unknown),Birgit E. P. J. Vriens,Yvonne van Riet,(unknown),Agnès J. van de Wouw,Ngoc Giang Le,Koen Venema,Sander S. Rensen,John Penders,Marjolein L. Smidt	28
9	Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry 2020 ·Quality of Life Research ·(unknown),Bram Ramaekers,D.J.A. Lobbezoo,Roel J.W. van Kampen,Maaike de Boer,Agnès J. van de Wouw,M. W. Dercksen,Sandra M. E. Geurts,Manuela Joore,Vivianne C. G. Tjan‐Heijnen	14
10	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. 2019 ·The Breast ·(unknown),Sandra M. E. Geurts,(unknown),Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,(unknown),D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
11	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study 2019 ·International Journal of Cancer ·Irene E.G. van Hellemond,Carolien H. Smorenburg,Petronella G.M. Peer,Astrid C P Swinkels,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	11
12	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure 2018 ·International Journal of Cancer ·Irene E.G. van Hellemond,Ingeborg J. H. Vriens,Petronella G.M. Peer,Astrid C P Swinkels,Carolien H. Smorenburg,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	7
13	Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium 2017 ·European Journal of Cancer ·Roel J.W. van Kampen,Bram Ramaekers,D.J.A. Lobbezoo,Maaike de Boer,M. Wouter Dercksen,F. Van den Berkmortel,Tineke J. Smilde,Agnès J. van de Wouw,Frank Peters,(unknown),Natascha A. J. B. Peters,V.C.G. Tjan-Heijnen,Manuela Joore	12
14	Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients 2017 ·Breast Cancer Research and Treatment ·B. Goorts,Thiemo J. A. van Nijnatten,Linda de Munck,M. Moossdorff,Esther M. Heuts,Maaike de Boer,Marc B. I. Lobbes,Marjolein L. Smidt	80
15	Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·B. Goorts,Stefan Vöö,Thiemo J. A. van Nijnatten,Loes Kooreman,Maaike de Boer,Kristien Keymeulen,Romy Aarnoutse,Joachim E. Wildberger,Felix M. Mottaghy,Marc B. I. Lobbes,Marjolein L. Smidt	21
16	Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10 years of follow up 2017 ·Radiotherapy and Oncology ·(unknown),J. Van Loon,Ruud Houben,(unknown),S. Engelen,(unknown),Maaike de Boer,Karolien Verhoeven,Dirk De Ruysscher,Liesbeth Boersma	15
17	Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases 2012 ·Annals of Oncology ·Maaike de Boer,Eddy Adang,(unknown),J.A.A.M. van Dijck,George F. Borm,(unknown),Carolien H. M. van Deurzen,P. J. van Diest,Peter Bult,A. Rogier T. Donders,Vivianne C. G. Tjan‐Heijnen	1
18	Non-Sentinel Lymph Node Metastases Associated With Isolated Breast Cancer Cells in the Sentinel Node 2008 ·JNCI Journal of the National Cancer Institute ·Carolien H. M. van Deurzen,Maaike de Boer,Evelyn M. Monninkhof,Peter Bult,Elsken van der Wall,Vivianne C. G. Tjan‐Heijnen,P. J. van Diest	85
19	Morphometry of Isolated Tumor Cells in Breast Cancer Sentinel Lymph Nodes: Metastases or Displacement? 2008 ·The American Journal of Surgical Pathology ·Carolien H. M. van Deurzen,Peter Bult,Maaike de Boer,Ron Koelemij,Richard van Hillegersberg,Vivianne C. G. Tjan‐Heijnen,Monique G. G. Hobbelink,Peter C. de Bruin,P. J. van Diest	11
20	Role of Negatively Charged Residues in the Fifth and Sixth Transmembrane Domains of the Catalytic Subunit of Gastric H+,K+-ATPase 1996 ·Journal of Biological Chemistry ·Herman G.P. Swarts,Corné H. W. Klaassen,Maaike de Boer,Jack Fransen,(unknown)	58

About Maaike de Boer

Maaike de Boer is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 74 papers that have together received 2.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (46 papers), Cancer Treatment and Pharmacology (16 papers) and Breast Lesions and Carcinomas (16 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.0k citations) and Pathology and Forensic Medicine (619 citations). Maaike de Boer has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Vivianne C. G. Tjan‐Heijnen, Peter Bult, J.A.A.M. van Dijck, P. J. van Diest, George F. Borm, George F. Borm, Carolien H. M. van Deurzen, Marian B. E. Menke‐Pluymers, Agnès J. van de Wouw and Marjolein L. Smidt. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact